October 24, 2007 – ev3 Inc. highlighted at TCT 2007 its merger with FoxHollow Technologies, Inc., which created an organization that possesses one of the largest U.S. distribution footprints in endovascular devices with combined technologies for the advancement of the treatment of peripheral and neurovascular disease.

October 23, 2007 – After 12 months of the SPIRIT III trial, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the original vessel blockage after using a Xience V everolimus-eluting coronary stent than a Taxus paclitaxel-eluting stent, researchers reported at TCT 2007.

October 23, 2007 - ENDEAVOR IV reached its primary endpoint of target vessel failure non-inferiority when compared to ...

October 23, 2007 - PLC Systems Inc. introduced at TCT 2007 the RenalGuard System, an investigational system and therapy ...

October 23, 2007 – Patients who received the CYPHER Sirolimus-eluting coronary stent had a lower risk of stent ...

October 22, 2007 - Implantation of the CYPHER Sirolimus-eluting Coronary Stent by Cordis Corp. used to treat completely ...

October 22, 2007 – Stent thrombosis rates through one year were low for both the TAXUS Express2 Paclitaxel-Eluting ...